Ophthalmic Drugs: World Market 2011-202121 Oct 2011 • by Natalie Aster
"I would say that the main areas are: dry AMD, particularly geographic atrophy (GA) - the most advanced and severe form of dry AMD; novel approaches to treating glaucoma, particularly neuroprotective strategies; and diabetic retinopathy. These are the main ones, in terms of greater market opportunity." (Dr Al Reaves, Senior Vice President of Clinical Development, Othera Pharmaceuticals, in a telephone interview with Visiongain).
The global ophthalmic pharmaceutical market will experience a declining growth rate during the period of 2009-2015. Generic competition in the leading area of the market, anti-glaucoma medications, will account for these decreased growth rates.
What are the Prospects for the Ophthalmic Pharmaceutical Market from 2016-2021?
Increasing numbers of elderly people and the consequent escalating occurrence of ophthalmic disease – especially glaucoma, AMD and DR – will stimulate demand for ophthalmic drugs from 2016 to 2021. Certain currently-marketed products, most notably Lucentis, will expand in sales by meeting that demand. Additionally, the launch of novel products to treat dry AMD, DR and offer neuroprotective benefits for glaucoma patients will add further revenues to the market by better meeting those demands.
Ophthalmic Drugs: World Market 2011-2021
Published: March 2011
Price: US$ 2,350.00
Report Sample Abstract
Merck & Co.'s Trusopt (dorzolamide) is a topical carbonic anhydrase III inhibitor, indicated in the treatment of elevated intraocular pressure in glaucoma and ocular hypertension. It was launched in Japan in 1999. Trusopt was launched in combination with the beta-blocker Timoptic (timolol), for instances of glaucoma and ocular hypertension unresponsive to therapy with either agent alone, as Cosopt in the US in 1998.
Trusopt is formulated as an eyedrop ophthalmic solution, with the usual dose being one drop twice daily. Cosopt was first launched in the UK and the US, and is now marketed worldwide. Trusopt was the eighth-leading anti-glaucoma brand in 2009
Combigan (brimonidine 0.2% + timolol 0.5%) is a combination of Allergan's Alphagan (brimonidine) with the beta-blocker timolol maleate. The product was first approved and launched in 2003 in Canada, and subsequently in Brazil in 2004. Combigan is indicated in the reduction of intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers. The first EU launch was in the UK in April 2005.
Extravan/Duotrav (travoprost 0.004%) + timolol 0.5%) is a fixed combination of the prostaglandin analogue travoprost with the Alcon’s timolol, a beta blocker developed for the treatment of glaucoma. It was first filed for approval in the US in January 2004. It was later approved in Canada, Europe and various other markets. From 2006 it was launched in Canada and across Europe. However, DuoTrav has still not yet been approved in the US. Alcon received notification from the FDA that it was approvable in September 2004, but further information was requested by the FDA. In early 2008 it was filed for approval in Japan and was recommended for approval in February 2010.
Generic Competition Will Affect the Anti-Glaucoma Market from 2009-2015
The global anti-glaucoma market will show a moderate increase in growth during the period 2009 to 2012. Increasing numbers of elderly people, and therefore glaucoma prevalence, will drive this modest growth. Prostaglandin analogue/prostamide brands and combinations of these with beta blockers will account for most of this growth, owing to their superior efficacy and dosing schedules.
To order the report or ask for sample pages contact firstname.lastname@example.org